贝伐单抗治疗晚期结直肠癌对病理显著缓解率及实验室指标的影响  

Effects of bevacizumab on major pathological response rate and laboratory index in advanced colorectal cancer

作　　者：郑波 赵红梅 郭鹏伟 王毅 崔海涛 ZHENG Bo;ZHAO Hongmei;GUO Pengwei(Department of General Surgery,Zhangjiakou First Hospital,Hebei,Zhangjiakou 075000,China;不详)

机构地区：[1]河北省张家口市第一医院普外科,075000 [2]河北省张家口市第五医院检验科

出　　处：《河北医药》2024年第18期2755-2758,共4页Hebei Medical Journal

基　　金：河北省医学科学研究课题(编号:20221886)。

摘　　要：目的分析贝伐单抗治疗晚期结直肠癌对病理显著缓解率(MPR)及实验室指标变化的影响。方法采取便利抽样的方法选取2021年1月至2022年10月张家口市第一医院收治的74例晚期结直肠癌患者,根据数字随机表法分作2组,对照组37例给予化疗,观察组37例于此基础给予贝伐单抗治疗,对2组患者的治疗效果、血清因子、肿瘤标志物及安全性进行比较。结果治疗后,观察组患者的MPR率为54.05%,客观缓解率(ORR)为56.76%,分别高于对照组的27.03%及32.43%(P<0.05)。观察组患者的血清基质金属蛋白酶-2(MMP-2)、基质金属蛋白酶-9(MMP-9)及血管内皮生长因子(VEGF)水平均低于对照组(P<0.05)。观察组患者的血清糖链抗原125(CA125)、癌胚抗原(CEA)、糖类抗原72-4(CA72-4)及糖类抗原19-9(CA19-9)表达均低于对照组(P<0.05)。观察组中不良反应的发生率是18.92%,低于对照组的40.54%(P<0.05)。结论贝伐单抗治疗晚期结直肠癌可取得显著效果,不仅能提高其治疗效果,改善血清因子、肿瘤标志物,而且还能促进患者的治疗安全性有效提高。Objective To analyze the effects of bevacizumab on major pathological response(MPR)rate and laboratory indices in patients with advanced colorectal cancer(CRC).Methods Seventy-four cases of advanced CRC were admitted to the First Hospital of Zhangjiakou from January 2021 to October 2022 were recruited by convenience sampling method,and they were randomly divided into control group(n=37,receiving chemotherapy)and observation group(n=37,receiving chemotherapy+bevacizumab).The therapeutic effects,serum factors,tumor markers and safety of the two groups were compared.Results After treatment,the MPR rate and objective remission rate(ORR)in the observation group were significantly higher than those of control group(54.05%vs 27.03%,56.76%vs 32.43%,P<0.05).The serum levels of matrix metalloproteinase 2(MMP2),matrix metalloproteinase 9(MMP9)and vascular endothelial growth factor(VEGF)in the observation group were significantly lower than the control group(P<0.05).The expression of serum cancer antigen 125(CA125),carcinoembryonic antigen(CEA),carbohydrate antigen 724(CA724)and carbohydrate antigen 19-9(CA19-9)in the observation group were significantly lower than the control group(P<0.05).The incidence of toxic side effects in the observation group was significantly lower than that in the control group(18.92%vs 40.54%,P<0.05).Conclusion Bevacizumab can achieve significant results in the treatment of advanced CRC.It not only improve the therapeutic effect,improve serum factors,tumor markers,but also promote the effective improvement of the safety of patients.

关 键 词：贝伐单抗 晚期结直肠癌 血清因子 肿瘤标志物 安全性 

分 类 号：R735.37[医药卫生—肿瘤]